First-in-human dose-escalation and expansion study (MITOPE) to evaluate mitochondrial PRX3 inhibition by RSO-021 in patients with mesothelioma and other advanced solid tumors
Authors
Dulloo, S.Fennell, D. A.
Szlosarek, P. W.
Thistlethwaite, Fiona C
Lord, S.
Rahman, N. M.
Greystoke, A.
Cunniff, B.
Dzialo, J.
Poile, C.
Panchal, R.
Duncan, J.
Graham, P.
Bexon, A. S.
Naumov, G.
Spicer, J.
Affiliation
Oncology Department, Leicester Royal Infirmary - University Hospitals of Leicester NHS Trust, LeicesterIssue Date
2022
Metadata
Show full item recordCitation
Dulloo S, Fennell DA, Szlosarek PW, Thistlethwaite F, Lord S, Rahman NM, et al. First-in-human dose-escalation and expansion study (MITOPE) to evaluate mitochondrial PRX3 inhibition by RSO-021 in patients with mesothelioma and other advanced solid tumors. Annals of Oncology. 2022 Sep;33(7):S1292-S3. PubMed PMID: WOS:000866211602195.Journal
Annals of OncologyDOI
10.1016/j.annonc.2022.07.1722Additional Links
https://dx.doi.org/10.1016/j.annonc.2022.07.1722Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2022.07.1722